Mylan sued for alleged patent infringement

PITTSBURGH Three drug companies have sued Mylan over an approval application the generic drug maker filed with the Food and Drug Administration for a version of the muscle relaxant Amrix, Mylan said Monday.

Mylan confirmed that Cephalon, Eurand and Anesta had sued it in connection with its application in the United States District Court for the District of Delaware, alleging an infringement of U.S. Patent No. 7,387,793.

Amrix is known generically as cyclobenzaprine hydrochloride. Mylan intends to market an extended-release formulation of the drug, which had sales of $53 million for the 12 months ending Sept. 30, according to IMS Health.